Google Parent-Owned Startup To Launch AI-Designed Drug Trials By Year-End, Partnering With Eli Lilly And Novartis To Tackle Major Diseases

Quick Summary:

A Google parent-owned startup is poised to begin clinical trials of its first artificial intelligence-designed drug by year-end, marking a significant milestone in pharmaceutical development as major tech companies increasingly invest in AI-powered healthcare solutions.

What Happened: Isomorphic Labs, an Alphabet Inc.(NASDAQ:GOOGL) subsidiary, is targeting major disease areas including oncology, cardiovascular conditions, and neurodegeneration, founder Demis Hassabis told Financial Times, speaking at the World Economic Forum in Davos.

The company has already secured partnerships with Eli Lilly and Co.(NYSE:LLY) and Novartis AG (NYSE:NVS) for six drug development programs.“It usually takes an ...

---

More Pictures

---

Read Quick SummarySave Time

or

Article Details

Author / Journalist: Kaustubh Bagalkote

Category: Technology

Markets: United States

Topics: Equities Benzinga neuro Benzinga US5324571083 LLY ORCL Markets GOOGL News NVS US38259P5089 US68389X1054 Health Care Biotech NTLA CRSP Artificial intelligence US66987V1098 Tech

Source Website Secure: Yes (HTTPS)

News Sentiment: Positive

Fact Checked: Legitimate

Article Type: News Report

Published On: 2025-01-22 @ 06:44:55 (12 hours ago)

News Timezone: GMT +8:00

News Source URL: benzinga.com

Language: English

Article Length: 311 words

Reading Time: 2 minutes read

Sentences: 15 lines

Sentence Length: 21 words per sentence (average)

Platforms: Desktop Web, Mobile Web, iOS App, Android App

Copyright Owner: © Benzinga

News ID: 25337665

View Article Analysis

About Benzinga

Main Topics: Technology

Official Website: benzinga.com

Update Frequency: 10 posts per day

Year Established: 2010

Headquarters: United States

News Last Updated: 10 hours ago

Coverage Areas: United States

Ownership: Independent Company

Publication Timezone: GMT +8:00

Content Availability: Worldwide

News Language: English

RSS Feed: Available (XML)

API Access: Available (JSON, REST)

Website Security: Secure (HTTPS)

Publisher ID: #53

Publisher Details

Frequently Asked Questions